MEP76708A - (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker - Google Patents
(imidazol-1-yl-methyl)-pyridazine as nmda receptor blockerInfo
- Publication number
- MEP76708A MEP76708A MEP-767/08A MEP76708A MEP76708A ME P76708 A MEP76708 A ME P76708A ME P76708 A MEP76708 A ME P76708A ME P76708 A MEP76708 A ME P76708A
- Authority
- ME
- Montenegro
- Prior art keywords
- disease
- compounds
- pyridazine
- imidazol
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02010217 | 2002-05-16 | ||
PCT/EP2003/005151 WO2003097637A1 (en) | 2002-05-16 | 2003-05-16 | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP76708A true MEP76708A (en) | 2011-12-20 |
Family
ID=29433072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-767/08A MEP76708A (en) | 2002-05-16 | 2003-05-16 | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker |
Country Status (31)
Country | Link |
---|---|
US (1) | US7005432B2 (ko) |
EP (1) | EP1506190B1 (ko) |
JP (1) | JP4267569B2 (ko) |
KR (1) | KR100632868B1 (ko) |
CN (1) | CN1312151C (ko) |
AR (1) | AR040010A1 (ko) |
AT (1) | ATE329912T1 (ko) |
AU (1) | AU2003242542B2 (ko) |
BR (1) | BR0311177A (ko) |
CA (1) | CA2485926C (ko) |
CL (1) | CL2004001251A1 (ko) |
CY (1) | CY1105159T1 (ko) |
DE (1) | DE60306152T2 (ko) |
DK (1) | DK1506190T3 (ko) |
ES (1) | ES2265581T3 (ko) |
HK (1) | HK1080845A1 (ko) |
HR (1) | HRP20041060B1 (ko) |
IL (1) | IL164922A (ko) |
MA (1) | MA27117A1 (ko) |
ME (1) | MEP76708A (ko) |
MX (1) | MXPA04011253A (ko) |
NO (1) | NO329605B1 (ko) |
NZ (1) | NZ536310A (ko) |
PL (1) | PL211340B1 (ko) |
PT (1) | PT1506190E (ko) |
RS (1) | RS51200B (ko) |
RU (1) | RU2317294C2 (ko) |
SI (1) | SI1506190T1 (ko) |
TN (1) | TNSN04224A1 (ko) |
WO (1) | WO2003097637A1 (ko) |
ZA (1) | ZA200408789B (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
KR101289923B1 (ko) * | 2005-05-03 | 2013-07-25 | 메르크 파텐트 게엠베하 | 유기 전계발광 장치 및 그에 사용되는 붕산 및 보린산유도체 |
US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
JP5315710B2 (ja) * | 2008-02-07 | 2013-10-16 | セントラル硝子株式会社 | 1−ブロモ−3−フルオロ−5−ジフルオロメチルベンゼンの製造方法 |
DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
JP2011516417A (ja) * | 2008-03-27 | 2011-05-26 | エヴォテック・ノイロサイエンシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Nmdanr2b−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
US8354411B2 (en) | 2009-02-05 | 2013-01-15 | Takeda Pharmaceutical Company Limited | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound |
EP2602255B1 (en) * | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
WO2012019106A2 (en) * | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
EP3180329B1 (en) * | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
CN109071488B (zh) | 2016-02-10 | 2021-08-13 | 詹森药业有限公司 | 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂 |
JP6850300B2 (ja) | 2016-02-18 | 2021-03-31 | シンジェンタ パーティシペーションズ アーゲー | 殺有害生物活性ピラゾール誘導体 |
WO2017158151A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
WO2017158147A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
JP7332472B2 (ja) | 2016-12-22 | 2023-08-23 | ノバルティス アーゲー | Nmda受容体モジュレーターおよびその使用 |
EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
CN112513047B (zh) | 2018-08-03 | 2023-10-20 | 诺华股份有限公司 | 芳香杂环nmda受体调节剂及其用途 |
AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
PE20220386A1 (es) | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
JOP20210330A1 (ar) | 2019-06-14 | 2023-01-30 | Janssen Pharmaceutica Nv | مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b" |
CN114007691A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 吡啶氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
MX2021015500A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. |
JP2022538795A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ピラジンカルバメート及びGluN2B受容体調節因子としての使用 |
CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0885004B1 (en) * | 1996-03-08 | 2002-05-02 | F.Hoffmann-La Roche Ag | Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers |
CA2220649C (en) * | 1996-12-03 | 2007-02-13 | F. Hoffmann-La Roche Ag | 4-hydroxy-piperidine derivatives |
US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
TWI254043B (en) * | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
DE60007697T2 (de) * | 1999-07-21 | 2004-12-09 | F. Hoffmann-La Roche Ag | Triazolderivate |
US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
KR100501606B1 (ko) * | 2000-04-20 | 2005-07-18 | 에프. 호프만-라 로슈 아게 | 피롤리딘 및 피페리딘 유도체, 및 신경퇴화성 질환의치료를 위한 그의 용도 |
US6432985B2 (en) * | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
US7022882B2 (en) | 2000-10-06 | 2006-04-04 | The Regents Of The University Of California | NMDA receptor channel blocker with neuroprotective activity |
CA2381630A1 (en) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
DE10120159A1 (de) | 2001-04-25 | 2002-10-31 | Merck Patent Gmbh | NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen |
US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
-
2003
- 2003-05-09 US US10/434,955 patent/US7005432B2/en not_active Expired - Fee Related
- 2003-05-15 AR ARP030101685A patent/AR040010A1/es active IP Right Grant
- 2003-05-16 KR KR1020047018485A patent/KR100632868B1/ko not_active IP Right Cessation
- 2003-05-16 ME MEP-767/08A patent/MEP76708A/xx unknown
- 2003-05-16 ES ES03752750T patent/ES2265581T3/es not_active Expired - Lifetime
- 2003-05-16 RS YUP-985/04A patent/RS51200B/sr unknown
- 2003-05-16 BR BR0311177-6A patent/BR0311177A/pt not_active IP Right Cessation
- 2003-05-16 EP EP03752750A patent/EP1506190B1/en not_active Expired - Lifetime
- 2003-05-16 NZ NZ536310A patent/NZ536310A/en not_active IP Right Cessation
- 2003-05-16 RU RU2004136979/04A patent/RU2317294C2/ru not_active IP Right Cessation
- 2003-05-16 DE DE60306152T patent/DE60306152T2/de not_active Expired - Lifetime
- 2003-05-16 SI SI200330332T patent/SI1506190T1/sl unknown
- 2003-05-16 DK DK03752750T patent/DK1506190T3/da active
- 2003-05-16 PL PL374224A patent/PL211340B1/pl unknown
- 2003-05-16 WO PCT/EP2003/005151 patent/WO2003097637A1/en active IP Right Grant
- 2003-05-16 JP JP2004505370A patent/JP4267569B2/ja not_active Expired - Fee Related
- 2003-05-16 MX MXPA04011253A patent/MXPA04011253A/es active IP Right Grant
- 2003-05-16 PT PT03752750T patent/PT1506190E/pt unknown
- 2003-05-16 AT AT03752750T patent/ATE329912T1/de active
- 2003-05-16 CA CA002485926A patent/CA2485926C/en not_active Expired - Fee Related
- 2003-05-16 CN CNB038111926A patent/CN1312151C/zh not_active Expired - Fee Related
- 2003-05-16 AU AU2003242542A patent/AU2003242542B2/en not_active Ceased
-
2004
- 2004-05-24 CL CL200401251A patent/CL2004001251A1/es unknown
- 2004-10-28 NO NO20044666A patent/NO329605B1/no not_active IP Right Cessation
- 2004-10-28 IL IL164922A patent/IL164922A/en not_active IP Right Cessation
- 2004-10-29 ZA ZA2004/08789A patent/ZA200408789B/en unknown
- 2004-11-11 TN TNP2004000224A patent/TNSN04224A1/fr unknown
- 2004-11-12 MA MA27943A patent/MA27117A1/fr unknown
- 2004-11-12 HR HR20041060 patent/HRP20041060B1/xx not_active IP Right Cessation
-
2006
- 2006-01-18 HK HK06100801A patent/HK1080845A1/xx not_active IP Right Cessation
- 2006-08-22 CY CY20061101161T patent/CY1105159T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP76708A (en) | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker | |
MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
ME00004B (me) | Derivati pirimidina | |
PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
DE60336850D1 (en) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
RS51795B (en) | 2-AMINO-7,8-DIHYDRO-6H-PIRIDO [4,3-D] PYRIMIDINE-5-ONE, A PROCEDURE FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
EP2039687A4 (en) | THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST MULTIPLE SCLEROSIS | |
MX2010002098A (es) | Compuesto policiclico. | |
WO2002060879A3 (en) | Bacterial gyrase inhibitors and uses thereof | |
SG11201407596TA (en) | Conjugation reagents | |
MA32558B1 (fr) | Composes organiques | |
RS54146B1 (en) | CIKLOPENTILAKRILAMIDA DERIVATIVES | |
MA30703B1 (fr) | Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii. | |
WO2001081309A3 (en) | 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol | |
MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
WO2007096740A3 (en) | Novel cephalosporins | |
EA014959B3 (ru) | Ингибиторы глицинового переносчика-1 | |
TN2010000231A1 (fr) | Derives de pyrazole servant d'inhibiteurs de 5-lo | |
MX2009011449A (es) | Agente terapeutico o profilactico para disquinesia. | |
EP2000473A4 (en) | TREHALOSE COMPOUND AND PHARMACEUTICAL PRODUCT COMPRISING THE SAME | |
AR057555A1 (es) | Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo | |
YU86501A (sh) | Derivati etansulfonil-piperidina | |
WO2008099781A1 (ja) | アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 | |
DE602007012435D1 (de) | Leukämie | |
NL2027866B1 (en) | Inhibitors of Nicotinamide N-methyl Transferase (NNMT) |